ZLAB News and Press, Zai Lab Limited From 02/05/26

2026-02-05 10:03:48 ET More on NovoCure NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Why NovoCure Is Failing To Disrupt NSCLC NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy Novocure reports F...

$207B Market Shift: The Race for Fast Track Approval in Oncology Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Feb. 5, 2026 /CNW/ -- USANewsGroup.com   News Commentary – The FDA isn't just approving drugs; they are completel...

2026-02-04 13:32:33 ET More on related tickers Trane Technologies: Upgrade To Buy On Cheaper Valuation And Better Fundamentals Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript Linde Q4 2025 Earnings Preview Genentech in up to $1.7B RNAi licensing dea...

2026-01-14 14:33:14 ET More on The Health Care Select Sector SPDR® Fund ETF XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins? Where To Find Outperformance In 2026 My S&P 500 Prediction On Sector Outperformers And Laggards In 2026 N...

2026-01-13 22:15:57 ET Zai Lab Limited (ZLAB) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 6:00 PM EST... Read the full article on Seeking Alpha For further details see: Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transc...

- Zocilurtatug pelitecan (Zoci) positioned to become Zai Lab’s first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC and NEC by the end of 2026 - Rapidly advancing a differentiated global pipeline, including ZL-1503 (IL-13xIL-31), ZL-6201 (...

2026-01-12 13:39:27 ET More on the markets Powell Under Attack The Bullish Trend Everyone Is Waiting For, But Nobody's Looking At DOJ Vs. Powell: We Have A Valuation Problem (And 2 Strategies For Now) Wall Street pushes higher despite Powell investigation ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market projected to reach $69.16 billion by 2032 as genomic profiling becomes stan...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotro...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, at 3:00 p.m. PST / 6:00 p.m. EST. A live webcast of the presentation...